tiprankstipranks
Advertisement
Advertisement
PremiumRatingsAnalyst Reiterates Buy on Eikon Therapeutics, Maintaining $29 December 2026 Price Target on Emerging Oncology Pipeline
1M ago
Premium
Company Announcements
Eikon Therapeutics Highlights Q1 2026 Results and Pipeline
1M ago
Opening Day: Generate Biomedicines makes public debut
Premium
The Fly
Opening Day: Generate Biomedicines makes public debut
3M ago
Eikon Therapeutics initiated with an Overweight at Morgan Stanley
PremiumThe FlyEikon Therapeutics initiated with an Overweight at Morgan Stanley
3M ago
Spotify upgraded, First Solar downgraded: Wall Street’s top analyst calls
Premium
The Fly
Spotify upgraded, First Solar downgraded: Wall Street’s top analyst calls
4M ago
Wedbush starts Eikon at Underperform on ‘significant clinical risk’
Premium
The Fly
Wedbush starts Eikon at Underperform on ‘significant clinical risk’
4M ago
Eikon Therapeutics indicated to open at $17.92, IPO priced at $18 per share
PremiumThe FlyEikon Therapeutics indicated to open at $17.92, IPO priced at $18 per share
4M ago
Eikon Therapeutics 21.18M share IPO priced at $18.00
Premium
The Fly
Eikon Therapeutics 21.18M share IPO priced at $18.00
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100